In the middle of June, the Food and Drug Administration approved Pembrolizumab (Keytruda) in combination with chemotherapy, followed by Keytruda alone, for the treatment of patients with advanced or recurrent endometrial cancer.
The approval was supported by results from a clinical trial enrolling 810 patients with advanced or recurrent endometrial cancer. Patients were randomly assigned to receive either Keytruda with chemotherapy, followed by Keytruda alone (study group), or placebo with chemotherapy, followed by placebo – same schedule (control group).
At the end of the follow-up period, the study results pointed towards a significantly lower risk of disease progression among the study group patients, compared to the control group patients.
Side effects associated with Keytruda and chemotherapy were generally similar to those previously reported for Keytruda or chemotherapy.
Keytruda in combination with chemotherapy offers a promising treatment option for patients with advanced or recurrent endometrial cancer.
Asking
Grasping
